trial

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

NCTId NCT01834638
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 268 (actual)
Sponsored by AbbVie
Primary completion 2014-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
268 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-03
Primary completion
2014-11
Eligibility
ALL · 20 Years · 66 Years

Interventions & indications

Drugs
ABT-126

Sponsors

AbbVieLead Sponsor

Investigators

1
George Haig, PharmDStudy Director

Sites

51 total
Chino, United StatesCosta Mesa, United StatesEscondido, United StatesGarden Grove, United StatesNational City, United StatesNorwalk, United StatesOakland, United StatesOceanside, United StatesOrange, United StatesPico Rivera, United StatesRiverside, United StatesSan Bernardino, United States

Linked catalysts

1
Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Exte — primary completion2014-11

Facts & assertions

4 sourced
Enrollment
268
Phase
PHASE2
Primary Completion Date
2014-11
Status
TERMINATED
relationships
The graph out of here
drug
ABT-126
drug
lead_sponsor
AbbVie
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
George Haig, PharmD
person